Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
作者信息
Cadeddu Jeffrey A
出版信息
J Urol. 2014 May;191(5):1290. doi: 10.1016/j.juro.2014.02.055. Epub 2014 Feb 22.
PMID:24745491
Abstract
摘要
相似文献
1
Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.关于：TOOKAD®可溶性血管靶向光动力（VTP）疗法：确定最佳治疗条件及评估局限性前列腺癌患者的疗效
J Urol. 2014 May;191(5):1290. doi: 10.1016/j.juro.2014.02.055. Epub 2014 Feb 22.
2
3
Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.关于：TOOKAD®可溶性血管靶向光动力（VTP）疗法：确定最佳治疗条件及评估局限性前列腺癌患者的疗效
J Urol. 2014 Apr;191(4):983-4. doi: 10.1016/j.juro.2014.01.075. Epub 2014 Jan 17.
4
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.使用WST11-血管靶向光动力（VTP）疗法确定实现局限性前列腺癌微创聚焦消融的最佳药物剂量和光剂量指数。
BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21.
5
Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).局部前列腺癌的血管靶向光动力疗法的中期随访：使用 TOOKAD 可溶性 WST-11（II 期试验）。
Eur Urol Focus. 2019 Nov;5(6):1022-1028. doi: 10.1016/j.euf.2018.04.003. Epub 2018 Apr 13.
6
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌：治疗程序的标准化
World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
7
Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.采用钯-细菌脱镁叶绿酸光敏剂的血管靶向光动力疗法治疗根治性放疗后复发性前列腺癌：安全性及治疗反应评估
J Urol. 2007 Nov;178(5):1974-9; discussion 1979. doi: 10.1016/j.juro.2007.07.036. Epub 2007 Sep 17.
8
TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.TOOKAD® 可溶性聚焦疗法：三项评估局限性前列腺癌微创消融的II期研究的汇总分析。
World J Urol. 2015 Jul;33(7):945-53. doi: 10.1007/s00345-015-1505-8. Epub 2015 Feb 25.
9
Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.使用TOOKAD® Soluble（WST11）进行血管靶向光动力疗法治疗局限性前列腺癌：自动预处理计划的效率
Lasers Med Sci. 2017 Aug;32(6):1301-1307. doi: 10.1007/s10103-017-2241-7. Epub 2017 Jun 1.
10
Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.基于蛙皮素拮抗剂的前列腺癌放射治疗联合 WST-11 血管靶向光动力疗法。
Clin Cancer Res. 2017 Jul 1;23(13):3343-3351. doi: 10.1158/1078-0432.CCR-16-2745. Epub 2017 Jan 20.
Zotero 插件